摘要
门静脉高压是导致肝硬化和肝癌患者不良预后的重要因素,其临床研究应强调多学科协同开展。当前,我国门静脉高压临床研究的质量和数量均有待提高。本文建议积极开展“创新技术应用驱动、多学科协作驱动、患者管理优化驱动”的临床研究,立足并服务于我国“门静脉高压共同体”建设。
Portal hypertension is an important predictor of the poor prognosis of patients with cirrhosis and hepatocellular carcinoma.The clinical research of portal hypertension should emphasize the cooperation of multidisciplinary team.At present,the quality and quantity of clinical research on portal hypertension in China need to be improved.Clinical research driven by innovative technology,multidisciplinary collaboration,and patient management optimization should be promoted.The clinical research should serve the construction of"a community of portal hypertension"in China.
作者
祁小龙
Qi Xiaolong(CHESS Center,Institute of Portal Hypertension The First Hospital of Lanzhou University,Lanzhou 730013,China)
出处
《中华肝脏病杂志》
CSCD
北大核心
2021年第9期817-819,共3页
Chinese Journal of Hepatology
关键词
门静脉高压共同体
临床研究
多学科协作
A community of portal hypertension
Clinical research
Multi-disciplinary collaboration
